drugset / Trial / NCT03946124

Fall Prevention in Older Adults With OAB

NCT03946124

Phase 4 Completed 74 enrolled University of Pennsylvania Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

Though OAB treatment may improve physical activity, there is a lack of easily administered instruments for measuring physical activity in older adults. Aim is to validate instruments to measure physical activity and preference for medication, and to determine the effect of preference for anti-cholinergic medication on adherence, physical activity, and falls risk. It's plan a prospective cohort study of adults aged 65 or older with OAB undergoing treatment with anti-cholinergic medication.

Timeline

Start
2015-07-25
Primary completion
2017-07-19
Completion
2017-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Fesoterodine Other / unclassified 4 mg
Subject Fesoterodine Other / unclassified 8 mg

Indications